Summary
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
Description
THE PHARMACEUTICAL MARKET: NEW ZEALAND - REVIEW
The macroenvironment for New Zealand's pharmaceutical market is restricted by low GDP and population size. Economically, New Zealand will be the smallest economy in the Asia Pacific region covered by Espicom in 2016. In terms of GDP per capita, however, New Zealand has a high rate for the region. Legally, New Zealand is a member of the WTO, and as a developed country it abides by the TRIPS agreement. However, the USTR remains concerned about the policies and operation of New Zealand's Pharmaceutical Management Agency (Pharmac). Demographically, the EIU projects that New Zealand will have the smallest population in the Asia Pacific region in 2016. The elderly population is expected to increase in the forecast period and will be the fourth highest rate in the Asia Pacific region. New Zealand is also restricted by the remoteness of its geographical location.
The Pharmaceutical Inspection Convention/Pharmaceutical Inspection Co-operation Scheme (PIC/S) Guidelines to Good Manufacturing Practice (GMP) PE 009-8, Parts I, II and Annexes 1 to 3, 6 to 15, 17, 19 and 20 have been adopted as the New Zealand Code of Good Manufacturing Practice for Manufacture and Distribution of Therapeutic Goods Part 1: Manufacture of Pharmaceutical Products. Therefore New Zealand adheres to the PIC/S guidelines on GMP and packaging for medicinal products. Pharmaceutical regulation is primarily the responsibility of New Zealand's Medicines and Medical Devices Safety Authority (Medsafe). This authority regulates all products used for a therapeutic purpose, using the Medicines Act 1981 and Regulations 1984. Medsafe is the regulatory agency responsible for overseeing pharmacovigilance activities.
Espicom expects the pharmaceutical market in New Zealand to grow at a low single-digit CAGR in US dollar terms during the forecast period. It will be the fourth smallest pharmaceutical market in the Asia Pacific region covered by Espicom in 2016. Very little pharmaceutical manufacturing takes place in New Zealand, with only a handful of companies operating factories in the country and no multinational manufacturing presence. This is partly due to Pharmac's, the government body responsible for pricing and reimbursement, strict policies that deter multinational companies from setting up operations. New Zealand is heavily dependent on the import of retail medicaments, which account for over three-quarters of the total imports.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
The Pharmaceutical Market: New Zealand published by Espicom Business Intelligence in January 31, 2013. This report consists of 77 Pages and the price starts from US $ 1295.
The contents of this page may be different from the latest version. Please contact us for details.
